Argenx : Green light from the FDA for Vygart Hytrulo in CIDP
>Vyvgart Hytrulo approved in CIDP - Last Friday evening, Vyvgart Hytrulo (subcutaneous version of Vyvgart) obtained FDA approval for use in chronic inflammatory demyelinating polyneuropathy (CIDP), the second indication approved in the US after Myasthenia Gravis (MG). The product has been granted a broad label and can therefore be prescribed for all patients with CIDP and throughout the treatment algorithm, which we consider to be a best-case scenario. This approval i...Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.